scholarly journals Approval rating and opinion of outpatients and general practitioners toward generic drugs: a questionnaire-based real-world study

2017 ◽  
Vol Volume 11 ◽  
pp. 1423-1433 ◽  
Author(s):  
Francesca Mattioli ◽  
Giacomo Siri ◽  
Francesca Castelli ◽  
Matteo Puntoni ◽  
Maria Laura Zuccoli ◽  
...  
Author(s):  
Fabiano Di Marco ◽  
Pierachille Santus ◽  
Silvia Terraneo ◽  
Elena Peruzzi ◽  
Elisa Muscianisi ◽  
...  

JMIRx Med ◽  
10.2196/24485 ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. e24485
Author(s):  
Moshe Rogosnitzky ◽  
Esther Berkowitz ◽  
Alejandro R Jadad


Author(s):  
Moshe Rogosnitzky ◽  
Esther Berkowitz ◽  
Alejandro R Jadad

UNSTRUCTURED Real-world drug repurposing—the immediate “off-label” prescribing of drugs to address urgent clinical needs—is an indispensable strategy gaining rapid traction in the current COVID-19 crisis. Although off-label prescribing (ie, for a nonapproved indication) is legal in most countries, it tends to shift the burden of liability and cost to physicians and patients, respectively. Nevertheless, in urgent public health crises, it is often the only realistic source of a meaningful potential solution. To be considered for real-world repurposing, drug candidates should ideally have a track record of safety, affordability, and wide accessibility. Although thousands of such drugs are already available, the absence of a central repository of off-label uses presents a barrier to the immediate identification and selection of the safest, potentially useful interventions. Using the current COVID-19 pandemic as an example, we provide a glimpse at the extensive literature that supports the rationale behind six generic drugs, in four classes, all of which are affordable, supported by decades of safety data, and pleiotropically target the underlying pathophysiology that makes COVID-19 so dangerous. Having previously fast-tracked this paper to publication in summary form, we now expand on why cimetidine/famotidine (histamine type-2 receptor antagonists), dipyridamole (antiplatelet agent), fenofibrate/bezafibrate (cholesterol/triglyceride-lowering agents), and sildenafil (phosphodiesterase-5 inhibitor) are worth considering for patients with COVID-19 based on their antiviral, anti-inflammatory, renoprotective, cardioprotective, and anticoagulation properties. These examples also reveal the unlimited opportunity to future-proof public health by proactively mining, synthesizing, and cataloging the off-label treatment opportunities of thousands of safe, well-established, and affordable generic drugs.


2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
A A Atramont ◽  
S C Coffy ◽  
S S Sebo ◽  
G D Debeugny

Abstract Methods A pay-for-performance scheme, known as Remuneration on public health objectives (ROSP) and based on meeting targets on quality and efficiency indicators, was introduced for general practitioners in France in 2012. Since 2017, following the 2016 medical agreement between Health Insurance and doctors’ unions, ROSP has consisted of 29 indicators: 8 about chronic disease management, 12 about prevention and 9 about appropriate and efficient prescriptions. The aim of this work was to describe the 2018 results and the overall evolution of the indicators for office-based practitioners. Data are from the French national health system database. Results Follow-up of diabetic patients is steady: diabetic retinopathy screening and regular HbA1c measurement have been performed in 63% and 79% of them since 2016, respectively. Screening for chronic kidney disease improved for diabetic patients (29% in 2015 to 39% in 2018) and hypertensive patients (6% to 11%) but remain low. Influenza vaccination among people over 65 years increased in 2018 (55%) while a downward trend has been observed since 2011 (58% in 2011, 53% in 2016). The number of antibiotic treatments has decreased since 2011, from 46 out of 100 adults without long-term disease to 36 in 2018. In contrast, breast cancer and cervical cancer screening indicators have stagnated for several years around 66% and 56%, respectively. In terms of efficiency, all the indicators improved, most of them consisting in biosimilar and generic drugs prescription. By 2018, ROSP represents 3% of doctors’ revenue (including fee-for-service and lump sum payments). Conclusions By promoting prevention, better management of chronic diseases and optimizing prescriptions in relation to standards, ROSP indicators contribute to improve medical practices. The indicators need to be regularly updated to take into account the evolution of practices and recommendations. Key messages By promoting prevention, better management of chronic diseases and optimizing prescriptions in relation to standards, ROSP indicators contribute to improve medical practices. The indicators need to be regularly updated to take into account the evolution of practices and recommendations.


Author(s):  
Berna Tuncay ◽  
Sergio Pagano ◽  
Mario De Santis ◽  
Pierpaolo Cavallo

The factors influencing General Practitioners’ (GPs) prescribing behavior are diverse in terms of health care policies and regulations, GPs’ education and experience, demographic trends and disease profiles. Thus, it can be useful to analyze the specific local patterns, as they affect the quality of healthcare and the stability of the healthcare market. The aim of the present longitudinal retrospective study is to investigate the prescription of generic drugs in a database of about 4.6 million prescriptions from a sample of 38 GPs practicing in Salerno, Italy, within a timeframe of 15 years, from 2001 to 2015. The GPs in our study show a general tendency to increase prescriptions of generic drugs during the studied time span, to fulfill regulatory obligations and with some differences in prescription behavior according to age, gender and experience. The generics prescription depends also on the different diagnoses, with some diagnostic areas showing a greater generic drug prescription rate. Expanding this research to larger datasets would allow deepening the knowledge of the patterns of GPs’ prescribing decisions, to provide evidence to be used in comparison between different national settings.


2011 ◽  
Vol 18 (4) ◽  
pp. 828-834 ◽  
Author(s):  
Wolfgang Spiegel ◽  
Marie-Theres Mlczoch-Czerny ◽  
Rolf Jens ◽  
Christopher Dowrick

2020 ◽  
Author(s):  
Bryce Brickley ◽  
Lauren T. Williams ◽  
Mark Morgan ◽  
Alyson Ross ◽  
Kellie Trigger ◽  
...  

Abstract Background: Patients, providers and health care organisations benefit from an increased understanding and implementation of patient-centred care (PCC) by general practitioners (GPs). This study aimed to evaluate and advance a theoretical model of PCC developed in consultation with practising GPs and patient advocates.Methods: Qualitative description in a social constructivist/interpretivist paradigm. Participants were purposively sampled from six primary care organisations in south east Queensland/northern New South Wales, Australia. Participants engaged in focus group discussions where they expressed their perceptions, views and feelings of an existing PCC model. Data was analysed thematically using a constant-comparison approach.Results: Three focus groups with 15 patient advocates and three focus groups with 12 GPs were conducted before data saturation was obtained. Three themes emerged: i) the model represents the ideal, ii) considering the system and collaborating in care and iii) optimising the general practice environment. The themes related to participants’ impression of the model and new components of PCC perceived to be experienced in the ‘real world’. The data was synthesised to produce an advanced model of PCC named, “Putting Patients First: A Map for PCC”.Conclusions: Our map represents an enhanced understanding of PCC in the ‘real world’ and can be used to inform patients, providers and health organisations striving for PCC. Qualitative testing advanced and supported the credibility of the model and expanded its application beyond the doctor-patient encounter. Future work could incorporate our map for PCC in tool/toolkits designed to support GPs and general practice with PCC.


2020 ◽  
Author(s):  
Moshe Rogosnitzky ◽  
Esther Berkowitz ◽  
Alejandro R Jadad

UNSTRUCTURED Author response to peer review for MS#19583


CHEST Journal ◽  
2017 ◽  
Vol 152 (4) ◽  
pp. A582
Author(s):  
Ruxandra Ulmeanu ◽  
Florin Mihaltan ◽  
Oana Arghir ◽  
Ovidiu Mladinescu ◽  
Gabriela Teodorescu

Sign in / Sign up

Export Citation Format

Share Document